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PENENTU GENETIK DALAM TINDAK BALAS TAC KEMOTERAPI 
DALAM PESAKIT KANSER PAYUDARA TIGA KALI NEGATIF 
 
ABSTRAK 
Kanser payudara tiga kali negatif (TNBC), salah satu subtip dalam kanser 
payudara yang dikategorikan sebagai fenotip yang agresif, kadar ulangan yang tinggi 
dan prognosis yang buruk dan merupakan cabaran klinikal yang penting kerana 
kekurangan terapi yang khusus. Walaupun, pesakit TNBC dirawat dengan regimen 
kemoterapi taxane, adriamycin dan cyclophosphamide (TAC), kerintangan ubatan dan 
pertumbuhan tumor ulangan adalah halangan utama dalam rawatan TNBC. Penanda 
prognostik bagi TNBC masih sukar difahami. Kajian ini dijalankan untuk menyelidik 
kesan SNP yang dipilih CYP1B1 142 C> G (rs10012), 4326 C> G (rs1056836) dan 
4390 A> G (rs1800440), CYP3A4 878 T> C (rs28371759), CYP3A5 6986 A > G 
(rs776746), ABCB1 1236 C> T (rs1128503), 2677 G> T / A (rs2032582) dan 3435 C> 
T (rs1045642) dan ekspresi gen serta tahap ekspresi miRNA yang dipilih (miR-21, 
miR-27b, miR-34a, miR-182, miR-200c dan miR-451) dalam memodulasi tindak 
balas kemoterapi TAC serta hasil rawatan pada pesakit TNBC. 
Tujuh puluh enam (76) sampel darah and 41 tisu blok FFPE dari pesakit yang sama 
disahkan secara klinikal dan histopatologi pesakit TNBC. DNA (sample darah) dan 
keseluruhan RNA (tisu blok FFPE) diekstrak. Pengenotipan dilakukan menggunakan 
kaedah PCR-RFLP and AS-PCR seterusnya penjujukan DNA. Tahap ekspresi mRNA 
dan miRNA diukur dengan menggunakan kaedah qRT-PCR. Kesan terhadap rawatan 
dan penyakit dinilai setelah selesai kemoterapi. Berdasarkan respon kemoterapi, 
Pesakit dibahagikan kepada kerintangan kemoterapi dan respon kemoterapi. Dalam 
analisis perkaitan genetik, genotip homozigot dan alel mutasi CYP1B1 4326 C>G dan 
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ABCB1 3435 C>T polimorfisme, gabungan genotip CYP1B1 142 GG + CYP3A4 878 
TT dan CYP1B1 4326 GG + ABCB1 1236 CT dan haplotip CYP1B1 4326G / 142C, 
ABCB1 3435T / 2677G / 1236T dan ABCB1 3435T / 2677T / 1236T  dikaitkan dengan 
risiko yang lebih tinggi untuk kerintangan kemoterapi. Manakala, genotip CYP1B1 
142 CG secara signifikan dikaitkan dengan respon kemoterapi yang baik. Untuk 
analisis ekspresi mRNA dan miRNA, tahap ekspresi tinggi bagi CYP1B1 dikaitkan 
secara signifikan dengan kerintangan kemoterapi. Lebih-lebih lagi, regulasi yang 
tinggi bagi miR-21 dan miR-182 didapati berkaitan dengan peningkatan risiko 
pengulangan penyakit menjadi lebih teruk dan menjadi faktor prognosis dalam pesakit 
TNBC yang menjalani kemoterapi TAC. Sebaliknya, genotip CYP1B1 142 CG 
dijumpai sebagai faktor prognostik yang baik untuk meramalkan kelangsungan hidup 
dalam pesakit TNBC. Oleh itu, genotip CYP1B1 4326 GG, ABCB1 3435 TT, tahap 
regulasi CYP1B1 mRNA yang tinggi dan tahap regulasi miR-21 dan miR-182 yang 
tinggi menjadi penentu genetik terhadap tindak balas kemoterapi TAC didalam pesakit 
TNBC. Penentu genetik ini boleh dipertimbangkan sebagai penanda bio yang 
berpotensi yang mungkin akan membantu pegawai perubatan, terutamanya dalam 
risiko berulang dan / atau prognosis yang berulang dan seterusnya meningkatkan 
pengurusan pesakit TNBC. 
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GENETIC DETERMINANTS OF TAC CHEMOTHERAPY RESPONSE IN 
TRIPLE NEGATIVE BREAST CANCER PATIENTS 
 
ABSTRACT 
Triple negative breast cancer (TNBC), one of the breast cancer subtypes is 
characterised by aggresive phenotype, high rates of recurrence and poor prognosis and 
is an important clinical challenge due to lack of specific targeted therapy. Although, 
TNBC patients are treated with taxane, adriamycin and cyclophosphamide (TAC) 
chemotherapy regimen, drug resistance and tumour recurrence are major obstacles in 
TNBC treatment. Reliable prognostic marker of TNBC remains elusive. The present 
study was undertaken to investigate the impact of selected SNPs of CYP1B1 142 C>G 
(rs10012), 4326 C>G (rs1056836) and 4390 A>G (rs1800440), CYP3A4 878 T>C 
(rs28371759), CYP3A5 6986 A>G (rs776746), ABCB1 1236 C>T (rs1128503), 2677 
G>T/A (rs2032582) and 3435 C>T (rs1045642) and their respective gene expressions 
as well as expression levels of selected miRNAs (miR-21, miR-27b, miR-34a, miR-
182, miR-200c and miR-451) in modulating TAC chemotherapy response and 
treatment outcome in TNBC patients. Seventy six (76) blood samples and 41 match 
paired FFPE tissues blocks available from the same group of clinically and 
histopathologically confirmed TNBC patients, who had undergone surgery and 
completed six cycles of TAC chemotherapy regimen were included in the study. DNA 
(blood samples) and total RNA (FFPE tissues blocks) were extracted. Genotyping was 
carried out using PCR-RFLP and AS-PCR methods followed by DNA sequencing. 
mRNA and miRNA expression levels were determined using qRT-PCR.  The 
treatment response and disease outcome  of the patients were evaluated after 
completion of chemotherapy. Based on chemotherapy response, patients were 
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categorized into chemoresistant and chemoresponse groups. In genetic association 
analysis, homozygous variant genotype and variant allele of CYP1B1 4326 C>G and  
ABCB1 3435 C>T polymorphisms, combination of CYP1B1 142 GG + CYP3A4 878 
TT and CYP1B1 4326 GG + ABCB1 1236 CT genotypes, CYP1B1 4326G/142C, 
ABCB1 3435T/2677G/1236T and ABCB1 3435T/2677T/1236T haplotypes were 
associated with significantly higher risk for chemoresistance. Whereas, CYP1B1 142 
CG genotype was significantly associated with good chemoresponse. For mRNA and 
miRNA expression levels analysis, high expression level of CYP1B1 was significantly 
associated with chemoresistance. Moreover, up regulation of miR-21 and miR-182 
were found to be associated with increased risk of relapse and to be a prognosis factor 
in TNBC patients undergoing TAC chemotherapy. On the other hand, CYP1B1 142 
CG genotype was found to be a good prognostic factor for predicting survival in TNBC 
patients. Thus, CYP1B1 4326 GG, ABCB1 3435 TT genotypes, high CYP1B1 mRNA 
expression level and up regulation of miR-21 and miR-182 expression levels emerged 
as genetic determinants of TAC chemotherapy response in TNBC patients. These 
genetic determinants could be considered as potential biomarkers that might help the 
clinician, especially in predicitng recurrence risk and/or prognosis and thus improve 
management of TNBC patients. 
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 CHAPTER 1 
INTRODUCTION 
1.1 Breast cancer 
Breast cancer is a type of cancer that develops in the cell lining of milk ducts as well 
as the lobules that supply the duct with milk. Breast cancer develops from normal 
breast epithelial cells that evolve via atypical hyperplasia (and eventually dysplasia) 
to ductal carcinoma in situ (DCIS) and subsequently to invasive breast cancer. The 
process involves multiple molecular alterations involving genetic and epigenetic 
alterations in precursor and neoplastic cells, subsequently turning to metastatic breast 
cancer (Rivenbark et al., 2013). 
 
Generally, breast cancer can be divided into two (2) types; sporadic and hereditary 
forms. The most common form of breast cancer is the sporadic form which accounts 
for more than 85% of cases. Sporadic breast cancer results from genetic changes that 
occur only in breast cancer cells (somatic mutation) due to exposure or interaction with 
environmental factors. However, hereditary breast cancer which accounts for less than 
15% of breast cancer cases, results from inherited germline mutations in high penetrant 
breast cancer susceptibility genes including breast cancer genes 1 and 2 (BRCA1 and 
BRCA2 genes) (Martin, 2001). 
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1.2 The incidence and prevalence of breast cancer  
Breast cancer is a global health issue and is the commonest form of cancer and the 
leading cause of cancer-related deaths in women (Beiki et al., 2012; Shah et al., 2014). 
The incidence is increasing worldwide over the years with high mortality rate. More 
than one million new breast cancer cases were reported which accounts for 25% of all 
cancer types (Ferlay et al., 2015). 
 
According to Globocan, the standardized incidence rate of breast cancer was 43.1 per 
100,000 population while the mortality rate was 12.9 per 100,00 population. The 
highest incidence was in Belgium (111.9 per 100,000), followed by Denmark (105 per 
100,000), Bahamas (98 per 100,000) and Netherlands (96 per 100,000). Continent 
wise, the incidence rate was highest in Northern America (91.6 per 100,000), followed 
by Western Europe (91.1 per 100,000), Middle Africa (26.8 per 100,000) and Eastern 
Asia (27 per 100,000) respectively (Ghoncheh et al., 2016a). Among South East Asian 
countries, Singapore had a higher incidence rate (65.7 per 100,000) followed by Brunei 
(48.6 per 100,000) and Philippines (47 per 100,000) (Youlden et al., 2014). 
 
According to the National Cancer Registry Malaysia report from 2007 to 2011, breast 
cancer was the commonest cancer type in women in Malaysia with a total of 18,343 
(17.1%) cases reported followed by colorectal (13.2%) and lung (10.2%). Breast 
cancer accounts for 32.1% of all cancer in females with life time risk of 1 in 30 
individuals and an age standardized rate of 31.1 per 100,000 in Malaysia (Azizah et 
al., 2016). 
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1.3 Breast cancer subtypes 
Breast cancer is a heterogenous malignancy and has many subtypes with different 
biological behaviour, clinic-pathological features and molecular characteristics 
(Yersal and Barutca, 2014). There are four major molecular subtypes of breast cancer; 
Oestrogen (ER) positive/luminal, Human epidermal growth receptor 2 (HER2) 
positive (HER2-enriched), basal-like and normal breast-like. However, recent study 
on the gene expression profiling revealed that breast cancer can be divided further into 
luminal A (ER positive and/or Progesterone (PR) positive, HER-2 negative), luminal 
B (ER positive and/or PR positive, HER-2 positive), HER-2 over expression (ER 
negative, PR negative, HER-2 positive) basal-like (ER negative, PR negative, HER-2 
negative, cytokeratin 5/6 positive and/or epidermal growth factor receptor 1 (HER-1) 
positive) as well as normal breast-like (Boyle, 2012).  
 
1.4 Breast cancer risk factors 
Several epidemiological studies have shown that genetic and environmental or 
interactions between these two factors play an important role in increasing the risk of 
breast cancer. Factors such as age, breast pathology, family history and genetic 
predisposition as well as environmental factors have been reported as risk factors for 
breast cancer development. However, other factors such as exposure to endogenous 
and exogenous hormone such as oral contraceptive pills as well as life style related 
factors also contribute to increased risk of breast cancer development (Abdulkareem, 
2013; Gotzsche and Jorgensen, 2013; Shah et al., 2014). 
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Age, gender and personal history: The risk of developing breast cancer increases 
with age as well as being a female gender. Breast cancer is uncommon before age of 
20 years. A study reported a rate of 10/100,000 for breast cancer in women aged below 
25 years and the risk increased up to 100 times in women by the age 45 years 
(Dumitrescu and Cotarla, 2005). Women have been reported to have a higher risk for 
breast cancer development as compared to men. However, men who are shown to 
express ER, PR and androgen receptors as well as men with Klinefelter’s syndrome 
have been reported to have a higher chance of breast cancer development (Murphy et 
al., 2006). Personal history such as diagnosed DCIS, stage IIB and hormone receptor 
negative are shown to pose a higher risk of breast cancer (Buist et al., 2010). So, also 
women who do not breast feed, pregnancy at early age, late menarche and early 
menopause are also reported to be at higher risk for breast cancer development 
(Collaborative Group on Hormonal Factors in Breast, 2002; Ritte et al., 2012). 
 
Breast pathology: Proliferative breast lesion without atypia, including usual ductal 
hyperplasia, intraductal papillomas, sclerosing adenosis and fibroadenomas may 
increase the risk of breast cancer development. Some studies showed that women with 
atypia had 4.3 folds higher risk of developing breast cancer as compared to a normal 
individual (Hartmann et al., 2005; Shah et al., 2014). 
 
Family history: History of breast cancer in the family especially among first/second 
degree relatives is one of the most important risk factors for the development of breast 
cancer (Martin et al., 2010a). Women with strong a family history of breast cancer 
may inherit some gene mutation that might influence the risk of breast cancer 
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development. In general, women with positive family history show early onset of 
breast cancer, bilateral breast cancer, advanced stage, positive lymph node, negative 
hormone receptors and a poorer prognosis (Verkooijen et al., 2006). Genetic factor is 
the most important factor that contribute to familial breast cancer development. A 
study showed that, women with inherited mutations in genes such as BRCA1, BRCA2, 
TP53, PTEN, STK1 had a higher risk for development of familial breast cancer (van 
der Groep et al., 2011). In fact, women with inherited mutations in BRCA1 had 40% 
to 85% lifetime risk of developing breast cancer and 25% to 65% for risk of developing 
ovarian cancer. On the other hand, those who have inherited BRCA2 mutation pose 
similar risk of breast cancer, with an ovarian cancer risk estimated to be 15% to 20% 
(Pruthi et al., 2010). 
 
Lifestyle and habits: Due to modernization, lifestyle habits are changing. Several 
epidemiological studies have shown that lack of physical activities, alcohol 
consumption, tobacco smoking, high fat diet, obesity and high cholesterol may 
increase the risk of breast cancer development (Khan et al., 2010). Alcohol 
consumption and tobacco smoking consist of various genotoxic agents such as reactive 
oxygen species (ROS), polycyclic aromatic hydrocarbon (PAH) and heterocyclic 
amines (HCA) that will lead to DNA damage in the cell. On the other hand, lack of 
physical activities and high fat diet increase the ER level in the body and thus increase 
the risk of breast cancer development and growth. 
 
Endogenous and exogenous exposure: Women who are exposed to ionizing 
radiation (medical diagnostic or therapeutic) and environmental carcinogens may have 
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higher risk of breast cancer. In addition, hormone replacement therapy (HRT) and 
usage of oral contraceptives are reported to increase the risk of breast cancer 
(Abdulkareem, 2013; Dumitrescu and Cotarla, 2005). Contraceptives pill contain the 
female sex hormones such ER and progestogens. These hormones prevent pregnancy 
by stopping the ovaries releasing eggs (called ovulation). However, these hormones 
can increase the growth of some breast cancers, which might explain why taking the 
pill slightly increases the risk of breast cancer. 
 
1.5 Screening and diagnosis of breast cancer 
Breast self-examination (BSE) and clinical breast examination (CBE) are the first line 
screening processes for breast cancer detection. Most clinicians encourage women to 
perform BSE monthly. These techniques will help to detect early signs of breast cancer 
including the presence of lump in the breast, a change of breast shape, dimpling of the 
skin, nipple discharge or presence of red scaly patch of the skin. Besides that, bony 
pain, malaise and loss of weight are other general signs of breast cancer. 
  
Advanced technique using automated machines such as mammography, ultrasound 
and magnetic resonance imaging are also being used in the screening and diagnosis of 
breast cancer. Mammography is an important technique in early detection of non-
palpable masses. However, routine mammography leads to undue stress and 
uncertainty in case of false positive results. Ultrasound helps clinician to screen breast 
cancers that could not be detected by mammography. However, MRI increase the 
modality in detection, assessment, staging and management of breast cancer (Shah et 
al., 2014). In addition, mammogram, MRI scan, ultrasound and CT scan are also used 
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to determine tumour growth and the metastatic spread to the lymph nodes, liver or 
other organs (Veronesi et al., 2005). For diagnosis, tissue biopsies are taken followed 
by staining and observation under a microscope. Based on the findings, the tissues, if 
cancerous will be classified according to the Tumour (T), Nodes (N), Metastasis (M) 
(TNM) system (see section 1.7). 
 
1.6 Histological staging and grading 
In breast cancer staging and grading, TNM system is used based on the size of tumour 
(T) and whether tumour has spread to the lymph nodes or not (N) or whether the 
tumour has metastasized to other parts of the body (M). Following breast cancer 
diagnosis, the patients are clinically staged using the American Joint Commission on 
Cancer (AJCC) (7th Edition, 2009) guidelines, whereas tumour is histologically graded 
according to the Scaff Bloom and Richardson (SBR) histological system (Tables 1.1 
and 1.2). Tumour grading compares breast cancer cells to the normal breast tissues and 
can be divided into three types; well differentiated (low grade), moderately 
differentiated (intermediate grade) and poorly differentiated (high grade) where the 
cells lose their features as compared to the normal breast cells.  
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Table 1.1: American Joint Commission on Cancer (7th Edition, 2009) guidelines -
tumour node metastasis (TNM) classification 
Primary tumour 
(T) 
 
TX Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
Tis Carcinoma in situ 
Tis (DCIS) Ductal carcinoma in situ 
Tis (LCIS) Lobular carcinoma in situ 
Tis (Paget’s) Paget’s disease of the nipple 
T1 Tumour ≤ 20 mm in greatest dimension 
T1mi Tumour ≤ 1 mm in greatest dimension 
T1a Tumour > 1 mm but ≤ 5 mm in greatest dimension 
T1b Tumour > 5 mm but ≤ 10 mm in greatest dimension 
T1c Tumour > 10 mm but ≤ 20 mm in greatest dimension 
T1 Tumour > 20 mm but ≤ 50 mm in greatest dimension 
T3 Tumour > 50 mm in greatest dimension 
T4 Tumour of any size with direct extension to the chest wall 
and/or to the skin (ulceration or skin nodules) 
T4a Extension to the chest wall, not including only pectoralis 
muscle adherence/invasion 
T4b Ulceration and/or ipsilateral satellite nodules and/or aedema 
(including peau d’orange) of the skin, which do not meet the 
criteria for inflammatory carcinoma 
T4c Both T4a and T4b 
T4d Inflammatory carcinoma 
Regional lymph 
nodes (N) 
 
NX Regional lymph nodes cannot be assessed (for example, 
previously removed) 
N0 No regional lymph node metastases 
N1 Metastases to movable ipsilateral level I, II axillary lymph 
node(s) 
N2 Metastases in ipsilateral level I, II axillary lymph nodes that 
are clinically fixed or matted; or in clinically detected 
ipsilateral internal mammary nodes in the absence of 
clinically evident axillary lymph node metastases 
N2a Metastases in ipsilateral level I, II axillary lymph nodes 
fixed to one another (matted) or to other structures 
N2b Metastases only in clinically detected ipsilateral internal 
mammary nodes and in the absence of clinically evident 
level I, II axillary lymph node metastases 
N3 Metastases in ipsilateralinfraclavicular (level III axillary) 
lymph node(s) with or without level I, II axillary lymph 
node involvement; or in clinically detected ipsilateral 
internal mammary lymph node(s) with clinically evident 
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level I, II axillary lymph node metastases; or metastases in 
ipsilateral supraclavicular lymph node(s) with or without 
axillary or internal mammary lymph node involvement 
N3a Metastases in ipsilateralinfraclavicular lymph node(s) 
N3b Metastases in ipsilateral internal mammary lymph node(s) 
and axillary lymph node(s) 
N3c Metastases in ipsilateral supraclavicular lymph node(s) 
Distant metastases 
(M) 
 
M0 No clinical or radiographic evidence of distant metastases 
cM0 (i+) No clinical or radiographic evidence of distant metastases, 
but deposits of molecularly or microscopically detected 
tumour cells in circulating blood, bone marrow, or other 
nonregional nodal tissue that are no larger than 0.2 mm in a 
patient without symptoms or signs of metastases 
M1 Distant detectable metastases as determined by classic 
clinical and radiographic means and/or histologically proven 
larger than 0.2 mm 
 
Table 1.2: Clinical staging-American Joint Commission on Cancer (7th Edition, 2009) 
guidelines 
Stage T N M 
Stage 0 Tis N0 M0 
Stage IA T1 N0 M0 
Stage IB T0 N1mi M0 
 T1 N1mi M0 
Stage IIA T0 N1 M0 
 T1 N1 M0 
 T2 N0 Mo 
Stage IIB T2 N1 M0 
 T3 N0 M0 
Stage IIIA T0 N2 M0 
 T1 N2 M0 
 T2 N2 M0 
 T3 N1 M0 
 T3 N2 M0 
Stage IIIB T4 N0 M0 
 T4 N1 M0 
 T4 N2 M0 
Stage IIIC Any T N3 M0 
Stage IV Any T Any N M1 
 
Table 1.1 and Table 1.2 were adapted from Shah et al., (2014) 
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1.7 Management and treatment of breast cancer 
Breast cancer is curable and treatable if detected early. The management and treatment 
of breast cancer depends on several factors including physical and biological 
characteristics of the disease, age, overall health and personal preferences of the 
patient. In treatment options, breast cancer is usually treated with surgery, 
chemotherapy, radiotherapy, hormonal and targeted therapies (Kabel and Baali, 2015) 
 
Surgery is the main treatment in breast cancer and depends on the type and stage of 
tumour. Patients will undergo lumpectomy or mastectomy. Lumpectomy is a surgical 
procedure in which only the part of the breast containing the cancer is removed, 
whereas mastectomy is a surgery in which the entire breast is removed, including all 
the breast tissue and sometimes other nearby tissues. On the other hand, a surgery such 
as sentinel lymph node biopsy (SLNB) or axillary lymph node dissection (ALSD) can 
also be done to determine the possibility of whether breast cancer has spread to axillary 
lymph nodes.   
 
Chemotherapy is a treatment where cancer cells are killed using single or combination 
of cytotoxic drugs either via intravenous or oral route. Usually, chemotherapy is 
administered to patients before, after or in place of surgery based on the stage of cases. 
Neoadjuvant chemotherapy is given to the patients before surgery to reduce or shrink 
the tumour size before undergoing surgery. On the other hand, adjuvant chemotherapy 
is given after the patients undergo surgery to improve the disease-free survival (DFS) 
and overall survival (OS) rates. 
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Radiotherapy uses high energy rays such as X-ray or other particles to kill cancer cells 
or to stop the cancer cell from growing. There are two types of radiation given to breast 
cancer patients 1) external beam radiation and 2) internal radiation. Radiotherapy will 
be given to breast cancer patients following breast conserving surgery, mastectomy or 
when cancer cells has spread to other parts of the body.  
 
Hormonal therapy is beneficial for breast cancer patients who are positive for 
oestrogen and progesterone receptor hormones. The therapy is given after or 
sometimes before surgery. Oestrogen has been known as an important factor for cancer 
cell growth and spread. Hormone therapy acts by lowering oestrogen levels or by 
stopping the oestrogen production, thus reducing the risk of cancer recurrence. It is 
recommended to breast cancer patients who are hormone positive (ER positive and/or 
PR positive) where tamoxifen is one of the drugs used in hormonal therapy acting by 
blocking the oestrogen receptors on breast cancer cells.  
 
Researchers have developed a new drug that can be targeted or specific to the targeted 
cells or protein by blocking the growth and spread of cancer cells. Targeted therapy is 
generally less likely than chemotherapy to harm normal, healthy cells. Breast cancer 
patients who are positive for human epidermal growth factor-2 (HER2) are normally 
recommended for targeted hormone treatment.  
 
 
12 
 
1.8 Breast cancer prevention 
Cancer prevention is the way to stop or reduce the risk of cancer development. One of 
the best ways to combat cancer is to prevent it from occurring by identifying and 
controlling the factors that may increase the risk for breast cancer development. As 
stated earlier, genetic and environmental factors or combinations of these two factors 
are closely related with higher risk of breast cancer.  
 
By routine practice of physical activity and healthy diet, one can reduce the risk of 
breast cancer. Physical activities can increase the rate of metabolism and oxygen 
uptake. It can also can increase metabolic efficiency and capacity and help to reduce 
blood pressure, insulin resistance as well as obesity. Increased intake of vegetables, 
fruits with high antioxidant and phytochemicals in diet and avoiding fatty foods, 
cigarette smoking as well as alcohol may also help lower the risk of breast cancer. 
 
Besides that, systematic screening and surveillance programmes could be addressed in 
order to fight against as well as reduce the mortality of breast cancer. Individuals who 
have family history of cancer, exposure to environmental carcinogens and common 
symptoms of breast cancer as mentioned earlier, should be more alertful and should 
take prudent steps to practise healthy lifestyles by monitoring their healths and 
undergoing routine medical check-up and cancer screening programmes. Breast cancer 
is treatable and curable if detected early. Early detection and early treatment may help 
to reduce the incidence and mortality rate of breast cancer. 
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1.9 Present study: Problem statement 
Triple negative breast cancer (TNBC) is one of the breast cancer subtypes, 
characterized by lack of ER, PR expressions and no amplification of the HER-2 
receptors. This subtype accounts for 15-20% of all breast cancer cases. TNBC is 
typically associated with high histological grade and stage, aggressive tumour 
phenotype showing only partial response to chemotherapy with lack of clinical 
established therapies (Kaplan et al., 2009). Moreover, TNBC is strongly associated 
with distant recurrence, visceral metastases and death when compared to other breast 
cancer types (Bauer et al., 2007; Dent et al., 2007). TNBC accounts for 15%-20% of 
the 500,000-breast cancer associated female deaths worldwide, each year and is 
considered as an international public health issue (Cancer Genome Atlas, 2012). In 
TNBC, recurrence often occurs within 1 to 3 years of diagnosis, while 5 years mortality 
rates appear to be increased following initial diagnosis. The median survival of 
advanced TNBC is at best 12 months, much lower than the median survival observed 
in other advanced breast cancer subtypes (Anders and Carey, 2009). 
 
Due to lack of target receptors (ER, PR and HER2) and lack of specific targets for 
treatment, patients diagnosed with TNBC do not benefit from hormonal or targeted 
therapy and has a high probability of having early tumour relapse following diagnosis. 
There has always been continuous search for novel therapeutic targets. Although 
effective tailored therapies have been developed for patients with hormone positive 
and HER-2 positive disease, TNBC patients are unlikely to benefit from currently 
available systemic therapy. At Hospital Universiti Sains Malaysia (Hospital USM) and 
several other centres, TNBC patients are treated with Taxane, Adriamycin and 
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Cyclophosphamide (TAC) chemotherapy regimen. TNBC seems to be particularly 
chemosensitive to taxanes and anthracyclines which is part of the standard regimens 
used for high risk patients. Since this subtype is associated with high risk of recurrence 
and metastasis, adjuvant chemotherapy using TAC regimen is given for early TNBC 
cases after the patients undergo primary surgical resection of their breast tumour and 
axillary nodes. Nevertheless, TNBC is generally susceptible to chemotherapy initially 
where early complete response does not correlate with overall survival. The risk of 
relapse within 3-5 years is higher than other breast cancer subtypes (Cheang et al., 
2008; Hudis and Gianni, 2011).  
 
TNBC is particularly lethal when it recurs. Drug resistance or disease recurrence is a 
major clinical manifestation and is the principle cause of TNBC related deaths. Due to 
tumour heterogeneity and interindividual differences in TNBC patients, the efficacy 
and toxicity of TAC chemotherapeutic drugs vary across individuals. As a result, a 
significant number of TNBC patients fail to respond or acquire resistance to the 
introduced TAC chemotherapeutic agents that usually leads to a relapse and worsening 
of prognosis. It has been shown that one out of two patients will fail to respond to 
initial treatments or will rapidly acquire resistance to chemotherapeutic drugs 
(O'Driscoll and Clynes, 2006). Since TNBC lacks specific target and clinical therapies, 
the availability of markers or signals that reliably differentiates between TAC 
chemotherapy sensitive and resistant patients are required to improve the 
chemotherapy. 
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In predicting the disease progression, the prospect of recurrence and treatment 
response, traditional clinical risk factors such as tumour size, patient’s age, regional 
lymph node spread, and ER receptor status are commonly used (Early Breast Cancer 
Trialists' Collaborative et al., 2008). However, the information derived from all these 
parameters are often unreliable in identifying who will respond better with TAC 
chemotherapy from others and who may end up with poor outcomes and recurrences. 
The causes for TNBC recurrence remain unknown. There is no acceptable module to 
investigate drug resistance and disease recurrence in TNBC. Hence, there is a pressing 
need to identify markers for TAC chemotherapy response in TNBC patients. This 
study aimed to investigate few putative genetic markers for their possible role in 
determining the TAC chemotherapy response, recurrence risk and treatment outcomes. 
 
1.9.1 Genetic determinants of variable chemotherapy response and recurrence 
risk 
Once the chemotherapeutic drugs enter a patient’s system and transits through the body 
to interact with cancer cell, the drugs interact with a diversity of molecular entities. 
During this process, patient’s genetics, especially germline-based variations can affect 
the pharmacokinetics of chemotherapeutic drugs and thus influence the bioavailability 
of these drugs. Pharmacokinetic variability also accounts for suboptimal therapeutic 
drug levels which results in decreased response. The factors accounting for suboptimal 
drug levels include variable metabolizing activities as well as different transporter 
activities. Genetic variations in the form of single nucleotide polymorphism (SNPs) 
that affect gene expression or function in individuals can cause interindividual 
differences in the metabolism and disposition of medications. Genetic variations in 
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genes encoding drug metabolizing enzymes and drug transporters could affect 
expression of corresponding proteins and can impact pharmacokinetics of 
chemotherapeutic drugs in patients and thereby may influence the intracellular 
delivery, effectiveness and response to those drugs. 
 
To date, genomic assays may be helpful in differentiating interpatient variability in 
identifying breast cancer patients who are likely to benefit (or not) and also in 
predicting disease recurrence. Genetic and epigenetic factors have been shown to be 
attributable to TNBC chemoresistance (O'Reilly et al., 2015; Ouyang et al., 2014). 
Differences in genetic variation among breast cancer patients have been identified to 
be important factors that contribute to differences in treatment response. SNPs of 
pharmacogenes might lead to absence or altered enzyme activity and show an impact 
on individual’s response or resistance to the treatment (Dumont et al., 2015). SNPs 
may affect drug toxicity and efficacy in a variety of ways. For example, SNPs located 
in coding sequence of a gene may result in amino acid change that may alter protein 
function when compared to wildtype protein. 
 
Drug transporters regulate the influx and efflux of drugs in cells. Genetic 
polymorphisms of transporters can have profound impact on drug disposition, drug 
efficacy and drug safety and thereby impact pharmacokinetics (Franke et al., 2008). 
Of particular interest has been on the pharmacogenetic relevance due to genetic 
variation in efflux transporters of the ATP-binding cassette (ABC) subfamily member 
B1 (ABCB1). As a transporter, ABCB1 has a broad affinity spectrum for different 
anticancer drugs including docetaxel, paclitaxel, doxorubicin etc.  
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Metabolism of a drug can also contribute to therapy resistance. The cytochrome P450 
(CYPs) enzymes facilitate the metabolism and elimination of nearly 50% of all 
chemotherapeutics drugs. In the metabolism of the drugs used in TAC chemotherapy 
regimen, the CYP3A4, CYP3A5 and CYP1B1 play major role. Genetic variations in the 
above CYP genes also can have profound effect on enzymes activity and thereby 
contribute to the variations in response to the chemotherapeutic drugs used for TNBC 
patients.  
 
Because genetic polymorphisms may affect the expression and activity of encoded 
proteins, it is a key covariate that is responsible for variability in drug metabolism, 
drug transport and for determining pharmacodynamics of drug effects. Cytochrome 
P450 (CYP1B1, CYP3A4 and CYP3A5) are drug metabolism enzymes and ABCB1 is 
drug efflux transporter that have been widely studied. SNPs in these drug metabolism 
and transport genes that may alter protein function are suggested to play an important 
role in determining the effectiveness of drugs and also in determining why some 
individuals are responsive or resistant to chemotherapeutic drugs. Since no reports are 
available on the impact of genetic variations in these drug metabolising or transporter 
genes on TAC chemotherapy response in TNBC patients, it was of interest to 
investigate whether genetic variations [SNPs] in CYP1B1 [142 C>G (rs10012), 4326 
C>G (rs1056836) and 4390 A>G (rs1800440)], CYP3A4 [878 T>C (rs28371759)], 
CYP3A5 [6986 A>G (rs776746)], ABCB1 [1236 C>T (rs1128503), 2677 G>T/A 
(rs2032582) and 3435 C>T (rs1045642)] have any impact in modulating TAC 
chemotherapy response and treatment outcome in TNBC patients. 
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Gene expression also plays an important role in chemotherapeutic response. For 
example, mRNA regulation is a process where the production of specific gene is 
increased or decreased. Deregulation of gene expression might play an important role 
in chemotherapeutic response. Alteration in drug metabolizing and transporter genes 
may reduce or increase the gene expression, and thus inactivate (or activate) the gene 
function. Hence, it was aimed to determine the mRNA expression levels of CYP1B1, 
CYP3A4, CYP3A5 and ABCB1 in cancerous as well as normal adjacent tissues and to 
correlate the gene expression levels with TAC chemotherapy response and treatment 
outcome in TNBC patients.  
 
Another aspect is epigenetic factors which also play important role in pharmacological 
response of chemotherapeutic drugs. Epigenetic factors such as microRNAs 
(miRNAs) represents a class of naturally occurring small non-coding RNA molecules. 
Through down regulating the expression of target genes, miRNAs play an important 
role in various biological processes including the proliferation, metastasis and 
chemoresistance of TNBC (Bockhorn et al., 2013). The silencing mechanism by which 
miRNAs regulate the expression of other genes might be one of the key factors 
regulating the cell specific expression as well as individual differences in the gene 
expression. Because of their high stability and specific expression pattern during 
tumorigenesis and progression, miRNAs have become attractive candidate biomarkers 
for cancer diagnosis and prognosis and novel target for cancer treatment. It has been 
shown that alterations in miRNA expression properties can be used to estimate and 
monitor the success of different therapeutic modalities (Zheng et al., 2010) and hence 
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miRNA expression are attractive novel aspects which can explain interindividual 
differences in drug response. Therefore, it was of interest to study few selected 
miRNAs with possible implications in modulating TAC chemotherapy response, 
predicting TNBC recurrence and treatment outcome. This study aimed to investigate 
the expression levels of selected miRNAs (miR-21, miR-27b, miR-34a, miR-182, 
miR-200c and miR-451) in cancerous and normal adjacent tissues and to correlate the 
miRNA expression levels with TAC chemotherapy response and treatment outcome 
in Malaysian TNBC patients. 
 
It was hypothesized that, an individual’s genomic profile especially genetic variations 
such as SNPs, expression of mRNAs and miRNAs within tumour samples may be able 
to identify characteristics that reflect tumour behaviour, response to treatment, disease 
progression and treatment outcome. Even though several studies have focused on the 
role of drug transporter and metabolism genes in genetic susceptibility to cancer, very 
little progress has been made in the identification of genetic and pharmacogenetic 
markers in modulating chemoresistance in TNBC patients. Therefore, the availability 
of genetic determinants that reliably differentiate between the chemotherapy regimen-
sensitive and resistant patients would improve breast cancer therapy. Currently, there 
are no genetic determinants available to predict the response of TNBC patients to TAC 
chemotherapy before initiation of treatment. It was hoped that this study which focuses 
on epigenetic (selected miRNAs expression) and pharmacogenetic alterations in drug 
metabolizing and drug transport enzymes (SNPs and mRNA expression) in TNBC 
patients undergoing (TAC) chemotherapy regimen might generate new information in 
this direction. 
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1.9.2 Objective(s) of the study 
The main objective of this study was to investigate the impact of selected SNPs of 
CYP1B1, CYP3A4, CYP3A5 and ABCB1, their mRNAs expression and expression 
levels of selected miRNAs in modulating TAC chemotherapy response and treatment 
outcome among TNBC patients. 
 
The specific objectives were: 
1. To investigate the genotype, allele and haplotype frequencies of the following 
polymorphisms (CYP1B1 142 C>G (rs10012), 4326 C>G (rs1056836) and 
4390 A>G (rs1800440), CYP3A4 878 T>C (rs28371759), CYP3A5 6986 A>G 
(rs776746), ABCB1 1236 C>T (rs1128503), 2677 G>T/A (rs2032582) and 
3435 C>T (rs1045642) in TNBC patients undergoing chemotherapy with TAC 
and determine the association of the genotypes and haplotypes of the 
investigated SNPs with chemotherapy response in TNBC patients. 
2. To investigate the mRNA expression level of CYP1B1, CYP3A4, CYP3A5, 
ABCB1 in cancerous and non-cancerous tissues of TNBC patients and to 
determine their association with clinicopathological variables and 
chemotherapy response 
3. To investigate the expression levels miRNAs (miR-21, miR-27b, miR-34a, 
miR-182, miR-200c and miR-451) in cancerous and non-cancerous tissues of 
triple negative breast cancer tissue patients and determine their contributory 
role in modulating chemotherapy response in TNBC patients. 
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4. To correlate the SNPs genotype pattern, mRNA and miRNA expression levels 
as well as clinicopathological variables with the relapse-free survival and 
overall survival of TNBC patients and evaluate their clinical significance. 
5. To evaluate whether all the above parameters could serve as predictive 
biomarkers of chemotherapy response and treatment outcome in TNBC 
patients undergoing TAC chemotherapy. 
 
1.9.3 Hypothesis 
Alternate hypothesis: There is association between candidate SNPs and mRNA 
expressions of CYP1B1, CYP3A4, CYP3A5 and ABCB1 and expression of selected 
miRNAs with TAC chemotherapy response in TNBC patients. 
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CHAPTER 2 
LITERATURE REVIEW 
2.1 Triple negative breast cancer (TNBC) 
Breast cancer is a heterogenous disease encompassing a variety of morphological and 
clinical distincts. As discussed in Chapter 1, breast cancer can be divided into five 
subtypes; luminal A, luminal B, HER-2 over expression, basal like and normal breast-
like. TNBC is defined by the lack of ER, PR expression and no amplification of HER-
2 (Elias, 2010). The term TNBC is referred to the immunohistochemically classified 
breast cancer showing absence of ER, PR and HER-2 protein expressions whereas the 
basal like subtype is defined by gene expression microarray analysis. TNBC is often 
but not always basal-like breast cancer (lack of ER, PR and HER-2 expressions), 
although there is a substantial overlap between TNBC tumour and basal like breast 
cancer (BLBC). There is significant heterogeneity within these largely overlapping 
subtypes (Turner et al., 2010). Seventy-five (75%) of BLBC is TNBC subtype and 
70% of TNBC is BLBC (Carey et al., 2006). On the other hand, most of BRCA-1 
mutant breast cancers are both TNBC and BLBC (Figure 1.3). 
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Figure 2.1: Similarities of TNBC, BLBC and BRCA-1 breast cancer (adapted from 
Hulsen et al., 2008) 
 
2.1.1 Incidence of TNBC 
Worldwide, the incidence of TNBC represents approximately 15-20% of newly 
diagnosed breast cancer cases (Bauer et al., 2007) where 170,000 of TNBC cases are 
diagnosed annually. The incidence of TNBC is higher in African-American women 
than other ethnic groups (Whites and Hispanics) (Clarke et al., 2012). The African-
American women had two-fold higher (4.1 per 100,000) incidence of TNBC than 
White (2.2 per 100,000) or Hispanic (2.1 per 100,000) (Amirikia et al., 2011).  
 
In Malaysia, the incidence of TNBC has been reported to range from 12.3% to 17.6% 
of the total breast cancer cases (Kanapathy Pillai et al., 2012; Tan et al., 2009). In other 
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population, the incidence of TNBC reported was 11.2% in Canada (Dent et al., 2007), 
13.0% in Singapore (Thike et al., 2010), 16.3% in United Kingdom (Rakha et al., 
2007), 14.0% in Japan (Nishimura and Arima, 2008), 20.4% in China (Qiu et al., 
2016a) and 19.9% in India (Patil et al., 2011). This indicates the disparity in TNBC 
incidence between the different ethnic groups in different countries. 
 
2.1.2 Risk factors associated with TNBC 
Some of the risk factors associated with TNBC development has already been 
mentioned in Chapter 1. However, there are several other risk factors reported to be 
associated higher risk of TNBC. TNBC frequently affects younger women. A study 
has shown that women under the age of 40 years had two-fold higher risk of being 
diagnosed as TNBC than women over 50 years of age. In addition, the age at diagnosis 
for TNBC is 5-10 years younger than non-TNBC patients (Newman et al., 2015; 
Trivers et al., 2009). Moreover, TNBC is reported to be more common in black women 
as compared to Whites (Trivers et al., 2009). In addition, African-American women 
had two times higher risk of getting TNBC compared to Whites and Hispanics 
(Amirikia et al., 2011). 
 
TNBC is overlapped with BRCA1 mutant breast cancer subtype. Thus, women with 
BRCA1 mutations have more than 50.0% chance of developing TNBC (Zhang et al., 
2012). A study by Gonzalez-Angulo et al. (2011) indicated that 20.0% of TNBC 
patients have positive BRCA1 mutations. Another study on Mexican TNBC patients 
showed that 23.0% of the patients had BRCA1 mutations (BRCA1 ex9-12del) 
(Villarreal-Garza et al., 2015). On the other hand, methylation at the promoter region 
